These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 28458287)

  • 1. [The Usefulness of Silkworms as a Model Animal for Evaluating the Effectiveness of Medicine and Food].
    Sekimizu K
    Yakugaku Zasshi; 2017; 137(5):551-562. PubMed ID: 28458287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of Novel Antibiotic Lysocin E Identified by Silkworm Infection Model].
    Hamamoto H; Sekimizu K
    Yakugaku Zasshi; 2017; 137(4):389-392. PubMed ID: 28381711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of Antibiotics Using Silkworm Bacteria and Fungi Infection Model].
    Hamamoto H; Sekimizu K
    Yakugaku Zasshi; 2018; 138(7):895-899. PubMed ID: 29962465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Identification of novel therapeutically effective antibiotics using silkworm infection model].
    Hamamoto H; Urai M; Paudel A; Horie R; Murakami K; Sekimizu K
    Yakugaku Zasshi; 2012; 132(1):79-84. PubMed ID: 22214583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of lysocin E using a silkworm model of bacterial infection.
    Hamamoto H; Sekimizu K
    Drug Discov Ther; 2016 Feb; 10(1):24-9. PubMed ID: 26911796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysocin E is a new antibiotic that targets menaquinone in the bacterial membrane.
    Hamamoto H; Urai M; Ishii K; Yasukawa J; Paudel A; Murai M; Kaji T; Kuranaga T; Hamase K; Katsu T; Su J; Adachi T; Uchida R; Tomoda H; Yamada M; Souma M; Kurihara H; Inoue M; Sekimizu K
    Nat Chem Biol; 2015 Feb; 11(2):127-33. PubMed ID: 25485686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of silkworm as a host animal for understanding pathogenicity of Cryptococcus neoformans.
    Ishii M; Matsumoto Y; Sekimizu K
    Drug Discov Ther; 2016 Feb; 10(1):9-13. PubMed ID: 26902902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silkworm pathogenic bacteria infection model for identification of novel virulence genes.
    Kaito C; Kurokawa K; Matsumoto Y; Terao Y; Kawabata S; Hamada S; Sekimizu K
    Mol Microbiol; 2005 May; 56(4):934-44. PubMed ID: 15853881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current use of silkworm larvae (Bombyx mori) as an animal model in pharmaco-medical research.
    Nwibo DD; Hamamoto H; Matsumoto Y; Kaito C; Sekimizu K
    Drug Discov Ther; 2015 Apr; 9(2):133-5. PubMed ID: 25994065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silkworm model of bacterial infection facilitates the identification of lysocin E, a potent, ultra-rapid bactericidal antibiotic.
    Hamamoto H
    J Antibiot (Tokyo); 2024 Aug; 77(8):477-485. PubMed ID: 38773231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Construction of a Platform for the Development of Pharmaceutical and Medical Applications Using Transgenic Silkworms].
    Sezutsu H; Sumitani M; Kondo M; Kobayashi I; Takasu Y; Suzuki T; Yonemura N; Iizuka T; Uchino K; Tamura T; Tsubota T; Tatematsu KI
    Yakugaku Zasshi; 2018; 138(7):863-874. PubMed ID: 29962462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a high-throughput strategy for discovery of potent analogues of antibiotic lysocin E.
    Itoh H; Tokumoto K; Kaji T; Paudel A; Panthee S; Hamamoto H; Sekimizu K; Inoue M
    Nat Commun; 2019 Jul; 10(1):2992. PubMed ID: 31278250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advantages of the Silkworm As an Animal Model for Developing Novel Antimicrobial Agents.
    Panthee S; Paudel A; Hamamoto H; Sekimizu K
    Front Microbiol; 2017; 8():373. PubMed ID: 28326075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of anti-diabetic drugs by using silkworm, Bombyx mori.
    Matsumoto Y; Sekimizu K
    Drug Discov Ther; 2016 Feb; 10(1):19-23. PubMed ID: 26961328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methicillin-resistant Staphylococcus aureus antibiotic resistance and virulence.
    Xia J; Gao J; Kokudo N; Hasegawa K; Tang W
    Biosci Trends; 2013 Jun; 7(3):113-21. PubMed ID: 23836034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hyperglycemic silkworm model for evaluating hypoglycemic activity of Rehmanniae Radix, an herbal medicine.
    Matsumoto Y; Sekimizu K
    Drug Discov Ther; 2016 Feb; 10(1):14-8. PubMed ID: 26902904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond conventional antibiotics for the future treatment of methicillin-resistant Staphylococcus aureus infections: two novel alternatives.
    Fitzgerald-Hughes D; Devocelle M; Humphreys H
    FEMS Immunol Med Microbiol; 2012 Aug; 65(3):399-412. PubMed ID: 22409572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus.
    Tabuchi F; Matsumoto Y; Ishii M; Tatsuno K; Okazaki M; Sato T; Moriya K; Sekimizu K
    J Antibiot (Tokyo); 2017 Jul; 70(8):907-910. PubMed ID: 28588223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Mycobacterium activity of microbial peptides in a silkworm infection model with Mycobacterium smegmatis.
    Yagi A; Uchida R; Hamamoto H; Sekimizu K; Kimura KI; Tomoda H
    J Antibiot (Tokyo); 2017 May; 70(5):685-690. PubMed ID: 28446822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drugs for methicillin-resistant Staphylococcus aureus: an update.
    Kumar K; Chopra S
    J Antimicrob Chemother; 2013 Jul; 68(7):1465-70. PubMed ID: 23429643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.